Full Press Release Details
Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
New Jersey, May 14, 2020/ -- Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information
technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address
the COVID-19 pandemic, has successfully completed its vaccine prototype. Premas obtained transmission electron microscopic (TEM)
images of the recombinant virus like particle (VLP) assembled in yeast during the past week which marks a significant milestone
and is believed by Premas to be one of the first in the world for VLP of SARS-CoV-2 virus. Premas, which is primarily responsible
for the development of the vaccine candidate through proof of concept, is collating data at this time and, collectively with Akers,
moving forward with conversations with regulatory authorities in India and continuing to develop a regulatory strategy in the
United States. A manufacturing protocol has also been established and large-scale production studies have been initiated for the
Kundu, Co-Founder and Managing Director at Premas
Biotech, commented, "We are delighted to announce the three protein VLP formation as confirmed from the TEM images and other
orthogonal analysis that have captured the distinct structural features of the VLP. The vaccine candidate is based on the three
COVID-19 proteins; Spike, Envelope and Membrane. We believe that this combination of three proteins distinguishes us from other
companies seeking to develop COVID-19 vaccines and makes the VLP promising as we work to proceed into pre-clinical trials."
Schreiber, Executive Chairman of Akers, stated, "We are encouraged by the recent progress made with Premas. As our next
step, we will present our findings to regulatory authorities with the intent of initiating pre-clinical trials this summer. We
will keep shareholders informed as we proceed through our milestones."
Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic
& vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation.
Besides D-CryptTM the difficult to express proteins expression platform, Premas' leading technologies include
Axtex-4D : an ex-vivo tissueoid generation platform and C-Qwence : a fully human naive India based scFv antibody
library. Further information is available on the Company's website: www.premasbiotech.com
email: contact@premasbiotech.com
Akers Biosciences Inc.
Biosciences is pursuing the development of a newly acquired license to a coronavirus vaccine candidate. In addition, the company
develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health related information
directly to the patient or clinician in a timely and cost-efficient manner. Akers has previously announced that that it had identified
the hemp and minor cannabinoid sectors as promising adjacent opportunities that could benefit from Akers' existing facility
and its core competencies.
information on the company and its products can be found at www.akersbio.com.
statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements
within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates,"
"assumes," "believes," "can," "could," "estimates," "expects,"
"forecasts," "guides," "intends," "is confident that", "may," "plans,"
"seeks," "projects," "targets," and "would," and their opposites and similar expressions
are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as
well as assumptions made by and information currently available to management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, changes in the market
acceptance of the company's products and services; challenges we may face in identifying, acquiring and operating new business
opportunities; the outcome of litigation or other proceedings to which the company is subject or which it may become subject to
in the future; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets
in which the company operates; the company's relationships with its key customers; adverse conditions in the industries
in which the company's customers operate; the company's ability to retain and attract senior management and other
key employees; the company's ability to quickly and effectively respond to new technological developments; the company's
ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others
and prevent others from infringing on the company's proprietary rights; the company's ability to achieve the expected
benefits and costs of the transactions related to the acquisition of Cystron Biotech, LLC, including, the timing of, and the company's
ability to, obtain and maintain regulatory approvals for clinical trials of the company's vaccine product candidate, the
timing and results of the company's planned clinical trials for its vaccine product candidate, the amount of funds the company
requires for its vaccine product candidate, and the company's ability to maintain its license with Premas Biotech PVT Ltd;
and the impact of the recent COVID-19 outbreak on the company's results of operations, business plan and the global economy.
A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the company's
filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission, as may be supplemented
or amended by the company's Quarterly Reports on Form 10-Q. The company disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Mass, Managing Partner